Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Impact of a Multidisciplinary Rehabilitation Program Associated With the Doado Application in Lowback Pain Management

NCT07061405 · tracked via the Priya Life Science France tracker
Sponsor
Phase
Not applicable
Started
2026-05
Last updated
2026-04-23

Condition(s) studied

Lumbar Pain Syndrome

Investigational drug(s) / intervention(s)

Multidisciplinary management associated with mobile application DoadoPhysiotherapy management alone associated with mobile application Doado

Multidisciplinary management associated with mobile application Doado: multidisciplinary program including physiotherapists, rheumatologists, physical medicine and rehabilitation specialists, occupational physicians, psychologists, etc., associated with Doado mobile application

Physiotherapy management alone associated with mobile application Doado: monodisciplinary physiotherapy rehabilitation program consisting of active treatment with a physiotherapist associated with Doado mobile application

Study summary

This study is aimed at patients consulting a physiotherapist for acute low-back pain at risk of becoming chronic.

The goal of this study is to compare two types of rehabilitation programs for these patients, on their functional disability at 3 months:

* A multidisciplinary program lasting two weeks, including physiotherapists, rheumatologists, physical medicine and rehabilitation specialists, occupational physicians, psychologists, etc.
* A monodisciplinary physiotherapy rehabilitation program consisting of active treatment with a physiotherapist, with 2 to 3 sessions per week for 4 to 5 weeks, based on muscle-strengthening exercises for the trunk and lower limbs and stretching exercises for the back and lower limbs.

Patients will be evaluated before treatment (baseline), and at 1, 3, 6 and 12 months to evaluate the following secondary outcomes: pain, absence of chronicity, evolution of functional disability, muscle endurance, flexibility, level of fear, apprehension and avoidance associated with low back pain over the time, return to work and to physical activities, painful relapses and analgesic treatment consumption.

Eligibility

Sex
ALL
Min age
20 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: Patient: 1. Suffering from acute common low back pain for less than 3 months at the time of the initial consultation 2. With a prescription for physiotherapy 3. Available for both programs 4. Aged between 20 and 55 5. Equipped with a smartphone compatible with the Doado application 6. Having been informed and having signed the free and informed consent form prior to any specific study procedure 7. Affiliated to a health insurance scheme Exclusion Criteria: Patient: 1. suffering from a first episode of acute common low back pain for less than one month at the time of the initial consultation 2. With a history of spinal surgery: 1. For lumbar arthrodesis in the 12 months prior to inclusion 2. For lumbar arthroplasty in the 6 months prior to inclusion 3. For lumbar recalibration or lumbar disc herniation within 3 months of inclusion. 3. With suspected specific low-back pain 4. Suffering from radiculalgia of the lower limbs 5. Suffering from sensory-motor disorders of the lower limbs 6. Suffering from continuous low-back pain for at least 3 months 7. Have severely impaired physical and/or psychological health, which in the investigator's opinion may affect the participant's compliance with the study. 8. Participating in other interventional research 9. In a period of exclusion from other research still in progress at the time of inclusion. 10. Protected: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision. 11. Pregnant, breast-feeding or parturient.

Primary outcome measure(s)

  • Functional disability — baseline, 3 months
    Oswestry disability Index (ODI): 10 questions with 6 possible answers each, to assess the impact of the pain on several life habits and functionalities (walk, personal care, sitting position, etc.). The score is expressed as a percentage of handicap between 0 and 100%.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Privé Saint Martin Pessac France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07061405 on ClinicalTrials.gov ↗ ← All trials in France